SCHEMBL1548083

SCHEMBL1548083

NC(=O)Nc1[nH]c2cc(Oc3ccc(N)cc3)ccc2c1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 3/20 0.43
CHEK2 O96017 1/20 0.40
BTK Q06187 3/20 0.38
ALDH1A1 P00352 5/20 0.37
GAA P10253 3/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 1/20 0.36
MITF O75030 1/20 0.36
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NLRP1 Q9C000 1/20 0.36
NOD2 Q9HC29 1/20 0.36
F13A1 P00488 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15045551 0.90 GPR17 (0.46) PARP10CHEK2BTKALDH1A1KMT2A
SCHEMBL1548067 0.89 CHEK2 (0.41) CHEK2KDM4EHSD17B10KMT2AMEN1
SCHEMBL12651132 0.87 GPR17 (0.34) PARP10CHEK2ALDH1A1GAAMAPT
SCHEMBL1548315 0.86 ALDH1A1 (0.51) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL13613410 0.85 PARP1 (0.41) BTKALDH1A1GAAMAPTKDM4E
SCHEMBL1548263 0.85 MEN1 (0.45) CHEK2BTKALDH1A1MAPTKDM4E
SCHEMBL9885160 0.83 GSK3B (0.42) HDAC1KIF11
SCHEMBL1547971 0.83 KDM4E (0.51) ALDH1A1GAAMAPTKDM4EHPGD
SCHEMBL1548405 0.82 MEN1 (0.38) ALDH1A1GAAMAPTKDM4EHPGD
SCHEMBL1548446 0.82 GRM5 (0.36) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2314575-B1 NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2013-06-19 EP disclosed
EP-2314575-B1 NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2013-06-19 EP disclosed
US-8445529-B2 Indole derivative having, carbamoyl group, ureido group and substituted oxy group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-05-21 US disclosed
US-8445529-B2 Indole derivative having, carbamoyl group, ureido group and substituted oxy group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-05-21 US disclosed
US-20110124668-A1 NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-05-26 US disclosed
US-20110124668-A1 NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-05-26 US disclosed
EP-2314575-A1 NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDE GROUP AND SUBSTITUTED OXY GROUP Santen Pharmaceutical Co., Ltd (JP) 2011-04-27 EP disclosed
EP-2314575-A1 NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDE GROUP AND SUBSTITUTED OXY GROUP Santen Pharmaceutical Co., Ltd (JP) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124668-A1 NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP IKBKB, CHUK, RELA PARP10 1479/4885CHEK2 923/4885BTK 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.